Company / Free Cash Flow
Jade Biosciences, Inc. Free Cash Flow History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$56.9M
FY2023
5-year range
-$56.9M / -$27.6M
FY2021-FY2023
Trend
-44.8%
vs FY2022
Sector context
#83 of 195
Health Care
What the data says
At -$57M, Jade Biosciences, Inc.'s free cash flow ranks #83 of 195 in the Health Care sector. Declined from -$28M to -$57M over the past 2 years.
Based on SEC 10-K filings.
-$57M in FY2023.
Declined from -$28M to -$57M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#83 of 195 in Health CareTop 43% of 195This company -$56.9M Sector average $465.6M
▼
-112.2% below sector average
Key checks
Key Insights
- In FY2023, free cash flow decreased 44.8% year-over-year.
- Ranks #83 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -$56.9M | -44.8% |
| FY2022 | -$39.3M | -42.6% |
| FY2021 | -$27.6M | - |
| FY2020 | - | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026